Eisai (OTCMKTS:ESALY) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “

Shares of OTCMKTS ESALY opened at $67.16 on Tuesday. The stock has a market cap of $19.92 billion, a PE ratio of 17.35 and a beta of 0.41. The company has a current ratio of 2.48, a quick ratio of 2.11 and a debt-to-equity ratio of 0.13. Eisai has a 12-month low of $63.85 and a 12-month high of $125.00. The company has a 50-day moving average of $69.39 and a 200 day moving average of $75.93.

Eisai (OTCMKTS:ESALY) last issued its earnings results on Wednesday, February 3rd. The company reported $0.65 earnings per share for the quarter. Eisai had a return on equity of 17.44% and a net margin of 16.86%. The business had revenue of $1.74 billion for the quarter. On average, sell-side analysts forecast that Eisai will post 2.28 EPS for the current fiscal year.

Eisai Company Profile

Eisai Co, Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures.

Featured Story: How to track put option volume

Get a free copy of the Zacks research report on Eisai (ESALY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.